IRCT20200624047908N1已完成3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients: a double-blind randomized clinical trial
Abadan University of Medical Sciences0 个研究点目标入组 1,000 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •One of the following signs: Fever = 37.8°C at any one time, Dry cough, Severe fatigue, Dyspnea
- •CT appearance compatible with COVID
- •O2 Saturation 94% or less
排除标准
- •Renal failure (eGFR < 30)
- •Bradycardia (HR < 50)
- •Taking amiodarone
- •Previous sofosbuvir use
- •Pregnancy/lactation
- •Multi-organ failure on admission (2 organs or more, excluding lung)
- •Requiring intubation on admission
- •Significant arrhythmia in EKG
- •Allergy to sofosbuvir or daclatasvir
- •Not consenting to the study
研究者
相似试验
已完成
2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
3 期
Hepatitis C Treatment in a Community-based SettingIRCT20170213032547N1Kerman University of Medical Sciences110
已完成
不适用
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70